Total Funding
66
75
Total FundingDebt Financing raised
Growth Score
-2 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
70022
Bright Path Labs patented advanced pharmaceutical manufacturing technology.
- Tony Quiñones: CEO & Board Member
- Michael Gonzalez: Chief Scientific OfficerPast Role: U.S. Environmental Protection Agency, Director for the Land Remediation and Technology Division
About the Company
An agile and patented advanced pharmaceutical manufacturing technology paving the way for rapid, low-cost, and scalable domestic API production. Bright Path Labs (BPL) is positioned to immediately fill gaps in the drug supply chain in response to the COVID-19 pandemic and other potential treatments or subsequently discovered vaccines and medicines
to address future health challenges. We have the physical and technical capacity for the agile research and development of advanced pharmaceutical manufacturing that is scalable, that helps us train a future workforce for research and is able to support Federal agencies to rapidly address drug shortages.
